Medications That Affect Bone Health: Risks & Mitigation Strategies

Medications That Affect Bone Health: Risks & Mitigation Strategies

Many commonly prescribed drugs negatively impact bone density or quality. Awareness enables proactive protection. Here's a breakdown by drug class.

Drug ClassMechanism of Bone HarmClinical ContextMitigation
Glucocorticoids (prednisone ≥5 mg/day × 3+ mo)↓ Osteoblastogenesis, ↑ osteoclast survival, ↓ Ca absorption, ↑ renal Ca loss, ↓ sex hormonesHighest risk: first 3–6 mo. Dose/duration dependent.Lowest effective dose; Ca/D supplementation; bisphosphonate if high risk; weight-bearing exercise; fall prevention.
Proton Pump Inhibitors (long-term)↓ Gastric acid → ↓ Ca carbonate absorption; possible ↓ osteoclast function via vacuolar ATPaseObservational: ↑ fracture risk (hip, spine, wrist) with >1 yr use.Use lowest dose/duration; switch to H2RA if possible; calcium citrate (acid-independent); monitor BMD.
Anticonvulsants (phenytoin, carbamazepine, phenobarbital, valproate)Induce CYP450 → ↑ vitamin D catabolism → ↓ Ca absorption; direct osteoblast toxicity (valproate)Chronic epilepsy populations.Vitamin D supplementation (target >30 ng/mL); consider newer AEDs (levetiracetam, lamotrigine); BMD monitoring.
Aromatase Inhibitors (letrozole, anastrozole, exemestane)Profound estrogen suppression → ↑ bone turnover, rapid lossBreast cancer adjuvant therapy (5–10 yrs).Baseline DEXA; bisphosphonate/denosumab if T-score < -1.5 or risk factors; exercise; Ca/D.
Androgen Deprivation Therapy (GnRH agonists/antagonists)Testosterone → estradiol conversion blocked → bone loss in menProstate cancer. 2–4% BMD loss/yr initially.Baseline DEXA; denosumab 60 mg q6mo or zoledronic acid q1yr; Ca/D; resistance training.
Antidepressants (SSRIs)Serotonin receptors on osteoblasts/osteoclasts; ↑ fall riskMeta-analyses: modest ↑ fracture risk.Fall risk assessment; consider non-SSRI if high fracture risk; BMD monitoring.
Loop Diuretics (furosemide)↑ Urinary Ca excretionHF, CKD, edema.Thiazide alternative if possible (thiazides ↓ Ca excretion); Ca supplementation; monitor.
Methotrexate (high-dose)↓ Osteoblast proliferation; folate antagonismOncology doses > rheumatology doses.Leucovorin rescue; Ca/D; BMD monitoring in long-term high-dose.
Depo-Provera (DMPA)Hypoestrogenism → BMD loss (reversible after discontinuation)Contraception; adolescents/young women concern for peak bone mass.Limit to 2 yrs if possible; Ca/D; weight-bearing exercise; consider alternatives.

Action Plan: Review med list with pharmacist/PCP annually. If on bone-harming therapy ≥3 months: baseline DEXA, Ca/D optimization, fall assessment, consider bone-protective agent per guidelines (AACE, NOF, ASCO).

Bones, Joints & Muscles - Related Articles